Use of nerve growth factor to treat congenital neurotrophic corneal ulceration.
OBJECTIVE
This study was designed to assess the efficacy of nerve growth factor in the treatment of neurotrophic corneal ulceration in a child with bilateral congenital corneal anesthesia secondary to trigeminal insufficiency.


METHODS
A 5-month-old child presented to the casualty department with a 2-week history of red eyes and right corneal ulceration. Slit-lamp examination showed a central defect in the right corneal epithelium with underlying stromal opacification, only mild conjunctival inflammation with slight decreased tear production, and otherwise apparently normal eyes. Initially this was investigated as an infected ulcer and treated for several weeks as herpetic ulceration with no beneficial effect. Further clinical examination demonstrated bilateral decreased corneal sensation along with decreased facial sensation in keeping with congenital trigeminal nerve insufficiency. Investigation with magnetic resonance imaging showed no obvious abnormality. Conservative treatment with lubricants resulted in progressive right corneal stromal loss, and no healing occurred in the left corneal ulcer. Bilateral large lateral tarsorrhaphies were performed. Despite this, the left corneal ulcer demonstrated no improvement and increasing stromal opacification was noted. Topical nerve growth factor (NGF) was then used to treat the left cornea and resulted in epithelial healing within 1 week. Treatment was continued for a further 10 days after epithelial healing. Despite conventional treatment on 3 separate occasions, further epithelial breakdown occurred. Topical NGF treatment resulted in a rapid improvement and healing of the epithelial defect.'At present, the patient is receiving a 6-month continuous treatment plan of NGF.


RESULTS
Persistent epithelial defects (PED) secondary to neurotrophic ulceration have responded to topical NGF on 3 separate occasions during a 2-year period. The corneal epithelium now remains intact, and the cornea has no vascularization; however, mild anterior stromal opacification has gradually increased despite prolonged NGF treatment.


CONCLUSIONS
NGF seems to represent a safe and efficacious treatment option to restore the integrity of corneal epithelium in which there is congenital corneal anesthesia because of trigeminal insufficiency. However, this treatment alone is insufficient to prevent progressive anterior stromal opacification.
Tan
Mei Hong
MH
Department of Ophthalmology, Oxford Eye Hospital, Radcliffe Infirmary, Oxford, United Kingdom.
Bryars
John
J
Moore
Jonathan
J
D003315:Cornea / Q000294:innervation*; D003320:Corneal Ulcer / Q000151:congenital / Q000188:drug therapy* / Q000473:pathology; D003389:Cranial Nerve Diseases / Q000151:congenital / Q000188:drug therapy* / Q000473:pathology; D019573:Epithelium, Corneal / Q000187:drug effects; D006801:Humans; D006987:Hypesthesia / Q000151:congenital / Q000188:drug therapy; D007223:Infant; D008297:Male; D020932:Nerve Growth Factor / Q000627:therapeutic use*; D009882:Ophthalmic Nerve / Q000187:drug effects* / Q000473:pathology; D009883:Ophthalmic Solutions / Q000627:therapeutic use
D009883:Ophthalmic Solutions; D020932:Nerve Growth Factor